The effects of dietary supplementation with Agaricales mushrooms and other medicinal fungi on breast cancer: evidence-based medicine

REVIEW

The effects of dietary supplementation with Agaricales mushrooms and other medicinal fungi on breast cancer: evidence-based medicine

Maria Rita Carvalho Garbi Novaes; Fabiana Valadares; Mariana Campos Reis; Daniella Rodrigues Gonçalves; Marilia da Cunha Menezes

Universidade de Brasília, School of Medicine, Institute of Health Science (ESCS), Brasília/DF, Brazil

ABSTRACT

Breast cancer is the most prevalent cancer in women. The most frequent therapeutic approaches for the treatment of this disease are chemotherapy, radiotherapy, hormone therapy, and surgery. Conventional pharmacological treatments cause many harmful side effects in patients. To improve the quality of life of breast cancer patients, researchers have sought alternative adjuvant treatment strategies. To assess the effects of fungi and other basidiomycetes Agaricales on the co-adjuvant treatment of breast cancer, we conducted a literary review of the available scientific evidence. We selected articles published in refereed journals from 1990 to 2011 in Medline, Lilacs, CAPES, Scielo, and Pubmed. Articles written in English, Spanish, and Portuguese were reviewed. We used the following descriptors: Agaricales, medicinal mushroom/fungus, breast cancer, dietary supplementation, synonyms, and related terms. The pharmacological effects of nutritional and medicinal mushrooms have been reported in several experimental clinical studies and have shown promising results in the adjuvant treatment of breast cancer. Adjuvant treatment with mushrooms is associated with improvements in the immunological and hematologic parameters of breast cancer, as well as in the quality of life of these patients. Randomized clinical studies are needed to elucidate the possible mechanisms of action and clinical benefits of these fungi with respect to survival time, disease progression, and metastasis in breast cancer.

Keywords: Nutritional supplement; Agaricus sylvaticus; Medicinal mushroom; Adjuvant treatment; Basidiomycetes.

INTRODUCTION

Breast cancer is highly prevalent in women. In 2008, the IARC/OMS estimated that breast cancer was the second biggest incidence of cancer in the world (1.29 million cases). In Brazil, it would be responsible for 49,000 new cases in women from 2010 to 2011 and the mortality rate for this type of cancer remains high, on one side, due to the fact that this disease continues to be diagnosed at advanced stages.^1,2

Treatment for breast cancer is complex and varies according to the histological diagnosis of the patient, the patient’s age, the disease stage and the therapeutic approaches taken.³

Factors associated with tumor growth and the conventional treatments used to treat cancer often result in malnutrition in breast cancer patients. Side effects caused by conventional treatments, significantly reduced caloric intake and decreased absorption of nutrients can all complicate cancer treatment and reduce the quality of life of cancer patients.⁴

Previous studies have sought to identify ways to improve the quality of life and nutritional status of cancer patients using adjuvant therapy with mushrooms.^4-10

The most recent studies hav e shown that dietary supplementation with Agaricales mushrooms and other medicinal fungi in breast cancer patients can provide benefits, such as antiproliferative and immunomodulatory effec ts on tumor cells.^11-15

The aim of this study is to analyze the effects of mushrooms and other basidiomycetous Agaricales as adjuvant treatments in breast cancer.

MATERIALS AND METHODS

A critical review of articles published in refereed journals between January, 1990 to March, 2011 was performed. Articles were identified in the Medline, Lilacs, Scielo, and Pubmed, Health Science Descriptors (DeCS) and Medical Subject Heading (MeSH) databases by searching for the following terms: in English (Agaricales, Agaricus, medicinal mushroom/fungus, breast cancer, dietary supplementation, edible mushroom effects, lectin), in Portuguese (caˆncer de mama, cogumelo medicinal), in Spanish (cáncer de mama, suplementación nutricional/dietética, cogumelos, hongos medicinales).

Articles identified in the indexing databases mentioned above, including both original articles and reviews of the bioactive effects of edible mushrooms on cancer, were selected for inclusion in this study. Experimental trials in animals evaluating the efficacy of medicinal fungi treatments in breast cancer and randomized clinical trials with Agaricales mushrooms (and other medicinal fungi) in humans with breast cancer were also included.

RESULTS AND DISCUSSION

Bioactive substances found in mushrooms and other Agaricales medicinal fungi

The therapeutic effects of medicinal mushrooms are due to the presence of lectin, β-glucan, ergosterol, arginine, and other bioactive substances in mushrooms.^5-9 The benefits and possible mechanisms of action of these substances are described in Table 1.

Lectins have been shown to be therapeutic agents with anticancer properties in animals and in clinical studies. They cause cytotoxicity and apoptosis and inhibition of tumor growth by preferentially binding to cancer cell membranes. Lectins function by sequestering the body’s polyamines, thereby inhibiting cancer cell growth. Lectins also alter the production of many interleukins, activate protein kinases, bind to ribosomes, and inhibit protein synthesis. In addition, lectins modify the cell cycle by inducing cell cycle arrest at the G2/M phase, promoting apoptosis, and stimulating nonapoptotic G1-phase accumulation mechanisms. Finally, lectins can also down-regulate telomerase activity and inhibit angiogenesis.^16-20

β-glucan is a glucose polymer present in medicinal mushrooms. It exhibits immunomodulatory effects as well as tumoricidal and antiproliferative activities in cancer patients through the stimulation of natural killer cells, neutrophils, monocytes, macrophages, and T-cells.^21-28

Ergosterol (or provitamin D2) is a precursor of ergocalci ferol, an important substrate in vitamin D biosynthesis and is found i n the lipid fraction of Agaricales extracts. This substanc e has antitumor, antiproliferation, and antimigratory effects on human cancer cells.^25-27 It has also been shown to inhi bit angiogenesis. In a study on sarcoma 180 cells, patients treat ed with ergosterol demonstrated delayed tumor growth with mi nimal side effects. For example, the decrease in lymphocyte count that is commonly caused by chemotherapy was not observed in these patients. Ergosterol appears to have no direct in vitro cytotoxic effects on tumor cells, although it inhibits tumor-induced neovascularization.²⁸

Arginine is a semi-essential amino acid used as a dietary supplement in cancer patients. It has been associated with a reduction of tumor growth and metastasis progression, and it is reported to have beneficial effects on the immune system, weight gain, and the time of survival of cancer patients.^29,30

A complete understanding of the actions of these fungi and their bioactive molecules in the prevention and treatment of cancer will require further investigation. However, research shows that many of these substances exert anticarcinogenic, antiviral, antithrombotic, antibiotic, and anti-inflammatory effects in addition to many other activities that provide health benefits.^5,6,9,31-32

Experimental studies with mushrooms and other Agaricales medicinal fungi

Promising results have been reported in animals and in vitro using medicinal mushrooms in the treatment of breast cancer and several other cancers.^33-49Table 2 provides a summar y of the studies mentioned below.

Takimoto et al.³³ demonstrated that rats administered Agaricus blazei extract orally exhibited increased cytotoxic Tlymphocyte growth, increased levels of interferon-gamma and an incre ase in NKcells when compared to water-treated controls. This study indicates that mushroom extracts estimulate cytotoxic activity on both, innate and adaptive immunological systems.

Immunomodulatory, antitumor, and antiproliferative effects o f lectin isolated from various types of Agaricaceae mushrooms have been demonstrated by Zhao et al.³⁴ The lectin contained in Agaricus bisporus has been shown to exhibit an antiproliferative effect on breast cancer cells, and the lectin contained in Tricholoma mongolicum has been shown to have an inhibitory effect on mastocytoma cells (P815) in vitro.

In an in vivo study, extracts of Coriolus versicolor promoted significa nt tumor reductions in mice inoculated with mastocyt oma tumor cells and mammary tumors. ³⁵

Chen et al.³⁶ examined the ability of an Agaricus bisporus extr act to inhibit aromatase at the estrogen receptor in vitro in MCF-7 cells and rat ovarian cells and in vivo in rats. The extr act inhibited cell proliferation. The linoleic and linolenic acid present in the extract inhibited aromatase activity by altering or mutating the active sites. The in vivo study sho wed that the extract decreased proliferation and tumor growth without affecting apoptosis in rats.

In studies of breast cancer cells (MFC-7), Grube et al. ³⁷ showed that Agaricus bisporus extract suppresses the activity of aromatase, resulting in a reduction of estrogen produc tion , which is a major contributor to postmenopausal breast canc er in women.

In experiments with breast cancer cells (MDA-MB-231), Thyagarajan et al.³⁸ showed that Ganoderma lucidum extract inhibits cell proliferation and the formation of new cellcolonies through the negative regulation of the expression of c-myc, an oncogene. The combination of G. lucidum extract with green tea extract demonstrated a synergistic effect by suppressing secretion of urokinase plasminogen, which is a breast c ancer cell activator, and thereby suppressed the growth and invasion of metastatic breast cancers.

In a study of breast cancer cells (MCF7), Petrova et al. ³⁹ noted that extracts of fungi significantly inhibited the reporter activity of nuclear factor-kappa b (NF-kb)by interfering negatively in its activation pathway. The study was conducted with 28 fungi extracts, 40% of which were found to inhibit NF-kb activity.

Gu & Leonard⁴⁰ reported the activities of 38 species of edible mushrooms in estrogen receptor-positive (MCF-7) and negative (MDA-MB-231, BT-20) human breast can cer cells. In aqueous extracts from Coprinellus sp., Flammulina velutipes, and Coprinus comatus, anticancer agents were identifie d that actively inhibited tumor growth.

Fang et al.⁴¹ conducted an in vitro investigation of fractions of ethyl acetate extracts from Shiitake mushrooms (Lentinus edodes) via biological assays of apoptosis and cell cycle analysis in two human breast carcinoma cell lines (MDA-MB-453 and MCF-7). The authors observed antipro liferative activity in all strains. Apoptosis was induced in 50% of the tumor cell lines via the positive regulation of bax, a pro-apoptotic protein. Cell cycle analysis revealed a decrease in the percentage of cells in S phase, an induction of cdk inhibitors and p21 and a suppression of CDK4 and cyclin D1 activities, thus indicating cell cycle arrest.

Studies using MCF-7 and MDA-MB-231 cells evaluated the effective ness of various types of edible mushroom extracts. Jedinak & Sliva,⁴² using flow cytometry, revealed that Pleorotus ostreatus inhibited the proliferation of these cells in breast and colon cancers via p53-dependent and p53 indepen dent mechanisms. This fungus exerted its effect by inducing the expression of the tumor suppressor p53 and the cyclin-dependent kinase inhibitor p21 (CIP1/WAF1), but at the same time inhibited the phosphorylation of retinoblastoma protein (Rb) in MCF-7 and HT-29 cells, breast and colon cells respectively.⁴²

A study by Jiang et al.⁴³ revealed that Ganoderma lucidum inhi bits proliferation of MDA-MB-231 breast cancer cells. By inhibitin g Akt and NF-kappab activity in MDA-MB-231 cells, Ganoderma lucidum reduced their growth.

Talorete et al.⁴⁴ isolated breast cancer cells (MCF-7) and exp osed them to an aqueous extract of Agaricus blazei. The resu lts indicated that this extract was able to reduce cell prolifera tion in 26% compared to the control group, by significa ntly enhancing the expression of an API gene regulatory complex in the human breast cancer cell line MC F7. This, again, highlights the anticarcinogenic potential of mushrooms.

In a study of rats inoculated with breast cancer cells, Vetvicka et al.⁴⁵ observed a reduction in cell proliferation after oral supplementation of β-glucan extracted from medicinal mushrooms. Likewise, a decrease in the prolif eration of cancer cells has been reported in studies carried out by Israilides et al.⁴⁶ with breast cancer cells (MCF-7) and by Sliva et al.⁴⁷ using the MDA-MB-231 cell line.

Clinical studies with breast cancer patients using Agaricales mushrooms and other medicinal fungi

Although there are some inconsistencies in the results of clinical studies regarding the use of medicinal mushrooms as an adjuvant therapy in breast cancer treatment, the majority of studies suggest a beneficial effect (Table 3).

A study in patients with breast cancer who received four daily doses (1.6 g each) of Agaricus sylvaticus revealed that Agaricus sylvaticus supplementation resulted in an increased number of natural killer (NK) cells in 75.7% of the patients. More than half of the patients were receiving chemotherapy or radiotherapy, which typically reduces the numbers of NK cells in the body. ^45,11

In a clinical study of various cancers, including breast cancer ( stage IV), Sliva et al.⁴⁷ provided patients with a complex of immunomodulatory components, including Agaricus blazei tea (10 mg/day). After six months of treatment, some patients had increased NK cell activity, as well as increased levels of TNF-α (tumor necrosis factor), erythroc ytes, hemoglobin, and glutathione. In contrast, the number of TNF-a receptors was reduced. Diarrhea and occasion al nausea were reported, but the quality of life had improve d. The combination of immune-active components was effective in increasing NK cell function and other immunological parameters in patients with advanced stages of cancer, thus providing an effective nutritional combina tion for the treatment of the late stages of cancer. ⁴⁷

Gennari et al.⁴⁸ reported a case study of a patient with breast cancer and showed that dietary supplementation with Agaricus sylvaticus increased the number of CD56+ NK cells in the blood and caused a total regression of lung metastasis.

Dolby ¹² reported that the D-fraction ob-D-Glucan (extracted from Maitake) and mushroom tablets of Grifola frondosa had a positive effect on the health status of the 15 breast cancer patients included in the study. This study reported an improve ment in the clinical parameters and laboratory test results of patients as well as improvements in their hemato logical parameters, red uctions in the amount of vomiting caused by chemotherapy, increased appetite and reduced anorexia, which can be a side effect of conventional treatments.

Hong et al.⁷ conducted a study with 362 breast cancer patients between 30 and 65 years of age. The frequency of ingestion of mushrooms was measured through a specific questionnaire. It was found that both the daily intake and the frequency of consumption were inversely related to the risk of breast cancer, especially in postmenopausal women. Similar results were reported by Shin et al. ¹⁴; however, in the Shin study, the consumption of medicinal mushrooms showed a strong protective effect against breast cancer in premenopausal women as well.

Several published experimental clinical studies have reported that medicinal mushrooms exhibit beneficial effects on the health and quality of life in breast cancer patients. The use of supplements as adjunctive therapies for the treatment of breast cancer has shown promising results, such as antiproliferative effects on tumor cells and immunomodulatory activities in the body. However, few articles have examined the effects of supplementation with medicinal mushrooms for the treatment of breast cancer. Therefore, new protocols for the purpose of conducting clinical trials are required to elucidate the possible mechanisms of action and clinical benefits of these fungi with respect to the survival time, clinical progression and quality of life of breast cancer patients.

ACKNOWLEDGMENTS

Financial Support: This review is part of a research project that was supported by the scholarship Scientific Iniciation Project -PIC from the Institute of Health Science -FEPECS.

AUTHOR CONTRIBUTIONS

Novaes MRCG participated at the heading, analysis and preparation of the manuscript, obtained a scholarship from the Scientific Iniciation Project of the Institute of Health Science -PIC/FEPECS. Valadares F, Reis MC, Gonçalves DR and Menezes MC were responsible for the collection and analysis of data and production of the final scientific work.

REFERENCES

1. Brazil. Ministry of Health Ministry of National Health Care National Cancer Institute [INCA]. Estimates October 20: incidence of cancer in Brazil. Rio de Janeiro, INCA, Brazil in 2009.

2. Guerra MR, Gallo CVM, Mendonça GAS. Risk of cancer in Brazil: trends and recent epidemiological studies. Rev Cancer. Brazil. 2005;51:227-34.

3. Brito C, Portela MC, Vasconcellos MTL. SUS oncological care to women w ith breast cancer in Rio de Janeiro. Rev Public Health. 2005;39:874-81.

4. Shang EC, Weiss S, Kaehler G. The Influence of Early Supplementation of Parenteral Nutrition on Quality of Life and Body Composition in Patients with Advanced Cancer. JPEN J Parenter Enteral Nutr. 2006;30:222-30, doi: 10.1177/0148607106030003222.

5. Novaes M RCG, Fortes RC. Antitumor effects of edible Agaricaceae mushroom s. Rev Nutr Bras. 2005;4:207-17.

6. Novaes MRCG, Novaes LCG. Drug-nutrient in edible mushrooms and o ther basidiomycetous Agaricales. Rev Bras Nutr Clin. 2005;20:181-7.

7. Hong SA, Kim K, Nam SJ, Kong G, Kim MK. A case-control study on the dietary int ake of mushrooms and breast cancer risk among Korean w omen. Int J Cancer. 2008;122:919-23, doi: 10.1002/ijc.23134.

8. Ahn WS, Kim DJ, Chae GT, Lee JM, Bae SM, Sin JI, et al. Natural killer cell activity and quality of life were improved by consumption of a mushroom extract, Agaricus blazei Murill Kyowa, in gynecological cancer patients undergoing chemotherapy. Int J Gynecol Cancer. 2004;14:589-94, doi: 10.1111/j.1048-891X.2004.14403.x.

9. Fortes RC, Novaes MRCG. The effects of Agaricus sylvaticus fungi dietary supplementation on the metabolism and blood pressure of patients with colorectal cancer during post surgical phase. Nutr Hosp. 2011;26:176-86.

10. Costa JV, Novaes MRCG, Asquieri ER. Chemical and antioxidant potential of Agaricus sylvaticus mushroom grown in Brazil. J Bioanal Biomed. 2011;3:049-054.

11. Gennari J, Gennari M, Fellipe JR. O Agaricus sylvaticus aumenta o número de células natural killer em pacientes com caˆncer. Revista de Medicina Complementar. 2001;7:42-9.

12. Dolby V. An extract from maitake mushroom is an important anti cancer. Better Nutr. 1997;59:38-59.

13. Kodama N, Komuta K, Nanba H. Can maitake MD-fraction aid cancer p atients? Altern Med Rev. 2002;7:236-9.

14. Shin A, Kim J, Lim SY, Kim G, Song MK, Lee ES, et al. Dietary mushroom i ntake and risk of breast cancer based on hormone receptor states. Nutr C ancer. 2010;62:476-83, doi: 10.1080/01635580903441212.

15. Jiang J, Sliva D. Novel medicinal mushroom blend suppresses growth and invasiveness of human breast cancer cells. Int J Oncol. 2010;37:1529 36, doi: 10.3892/ijo–00000689.

16. Sendra VG, Zlocowski N, Nores GA, Irazoqui FJ. Anti-idiotypic antibody mimicking a T-antigen-specific lectin inhibits human epithelial tumor cell proliferation. Immunol Cell Biol. 2010;88:787-94, doi: 10.1038/icb. 2010.49.

17. Zhang GQ, Sun J, Wang HX, Ng TB. A novel lectin with antiproliferative activity from the medicinal mushroom Pholiota adiposa. Acta Biochim Pol. 2009;56:415-21.

18. Yang N, Li DF, Feng L, Xiang Y, Liu W, Sun H, et al. Structural basis for the tumor cell apoptosis-inducing activity of an antitumor lectin from the edible mushroom Agrocybe aegerita. J Mol Biol. 2009;387:694-705, doi: 10.1016/j.j mb.2009.02.002.

19. De Mejí a EG, Prisecaru VI. Lectins as bioactive plant proteins: a potential in cancer treatment. Crit Rev Food Sci Nutr. 2005;45:425-45, doi: 10.1080/ 10408390591034445.

20. Wang HX, Liu WK, Ng TB, Ooi VE, Chang ST. The immunomodulatory and antitu mor activities of lectins from the mushroom Tricholoma mongolicu m. Immunopharmacology. 1996;31:205-11, doi: 10.1016/0162 3109(95)00049-6.

21. Fujimiya Y, Suzuki Y, Oshiman K, Kobori H, Moriguchi K, Nakashima H, et al. Selective tumoricidal effect of soluble proteoglucan extracted from the basidiomycete, Agaricus blazei Murill, mediated via natural killer cell activation and apoptosis. Cancer Immunol Immunother. 1998;46:147-59, doi: 10.1007/s002620050473.

22. Kodama N, Komuta K, Nanba H. Effect of Maitake (Grifola frondosa) D- Fraction on the activation of NK cells in cancer patients. J Med Food. 2003;6:371- 7, doi: 10.1089/109662003772519949.

23. Demir G, Klein HO, Mandel-Molinas N, Tuzuner N. Beta glucan induces proliferation and activation of monocytes in peripheral blood of patients with advanced breast cancer. Int Immunopharmacol. 2007;7:113-6, doi: 10.1016/j.intimp.2006.08.011.

24. Zhang M, Chiu LC, Cheung PC, Ooi VE. Growth-inhibitory effects of a beta-gluca n from the mycelium of Poria cocos on human breast carcinoma MCF-7 cells: cell-cycle arrest and apoptosis induction. Oncol Rep. 2006;15:637-43.

25. Thohinung S, Kanokmedhakul S, Kanokmedhakul K, Kukongviriyapan V, Tusskorn O, Soytong K. Cytotoxic 10-(indol-3-yl)-[13]cytochalasans from the fungus Chaetomium elatum ChE01. Arch Pharm Res. 2010;33:1135-41, doi: 10.1007/s12272-010-0801-5.

26. Wu JY, Zhang QX, Leung PH. Inhibitory effects of ethyl acetate extract of Cordyceps sinensis mycelium on various cancer cells in culture and B16 melanoma in C57BL/6 mice. Phytomedicine. 2007;14:43-9, doi: 10.1016/j. phymed.2005.11.005.

27. Lee DY, Lee SJ, Kwak HY, Jung L, Heo J, Hong S, et al. Sterols isolated from Nuruk (Rhizopus oryzae KSD-815) inhibit the migration of cancer cells. J Microbiol Biotechnol. 2009;19:1328-32.

28. Takaku T, Kimura Y, Okuda H. Isolation of an Antitumor Compound from Agar icus blazei Murill and Its Mechanism of Action. J. Nutr. 2001;131:1409-13.

29. Zhang D, Jiang P, Xu Q, Zhang X. Arginine and Glutamate-rich 1 (ARGLU1) Interacts with Mediator Subunit 1 (MED1) and Is Required for Estrogen Receptor-mediated Gene Transcription and Breast Cancer Cell Grow th. J Biol Chem. 2011;286:17746-54, doi: 10.1074/jbc.M110. 206029.

30. Tada N, Horibe T, Haramoto M, Ohara K, Kohno M, Kawakami K. A single replacement of histidine to arginine in EGFR-lytic hybrid peptide demonstrates the improved anticancer activity. Biochem Biophys Res Commun. 2011;407:383-8, doi: 10.1016/j.bbrc.2011.03.030.

31. Fortes RC, Melo AL, Recôva VL, Novaes MRCG. Alteraço˜es lipídicas em pacientes com caˆncer colorretal em fase pós-operatória: ensaio clínico randomizado e duplo-cego com fungos Agaricus sylvaticus. Rev bras. colo-proctol. 2008;28:281-8.

32. Fortes RC, Novaes MRCG. Effects of dietary supplementation with Agaricales mushrooms and other fungi in medicinal therapy against cancer. Revista Brasileira de Cancerologia. 2006;52:363-71.

33. Takimoto H, Wakita D, Kawaguchi K, Kumazawa Y. Potentiation of cytotoxic activity in naı¨ve and tumor-bearing mice by oral administra tion of hot-water extr acts from Agaricus brazei fruiting bodies. Biol Pharm Bull. 2004;27:404-6, doi: 10.1248/bpb.27.404.

34. Zhao C, Sun H, Tong X, Qi Y. An antitumour lectin from the edible mushroom Agrocybe aegerita. Biochem J. 2003;374:321–7, doi: 10.1042/ BJ20030300.

35. Chu KK, Ho SS, Chow AH. Coriolus versicolor: a medicinal mushroom with pro mising immunotherapeutic values. J Clin Pharmacol. 2002;42:976-84.

36. Chen S, Oh SR, Phung S, Hur G, Ye JJ, Kwok SL, et al. Anti-aromatase activity of phytochemicals in white button mushrooms (Agaricus bisporus). Cancer Res. 2006;66:12026-34, doi: 10.1158/0008-5472.CAN-06-2206.

37. Grube BJ, Eng ET, Kao YC, Kwon A, Chen S. White button mushroom phytochemicals inhibit aromatase activity and breast cancer cell proliferation. Journal of Nutrition. 2001;131:3288-93.

38. Thyagarajan A, Zhu J, Sliva D. Combined effect of green tea and Ganoderma lucidum on invasive behavior of breast cancer cells. Int J Oncol. 2007;30:963-9.

39. Petrova RD, Mahajna J, Reznick AZ, Wasser SP, Denchev CM, Nevo E. Fungal substantiate modulators of NF-kappaB activation pathway. Mol B iol Rep. 2007;34:145-54, doi: 10.1007/s11033-006-9027-5.

40. Gu YH, Leonard J. In vitro effects on proliferation, apoptosis and colony i nhibition in ER-dependent and ER-independent human breast cancer c ells by selected mushroom species. Oncol Rep. 2006;15:417-23.

41. Fang N, Li Q, Yu S, Zhang J, He L, Ronis MJ, et al. Inhibition of growth and induction of apoptosis in human cancer cell lines by an ethyl acetate fraction from shiitake mushrooms. J Altern Complement Med. 2006;12:125-32, doi: 10.1089/acm.2006.12.125.

42. Jedinak A, Sliva D. Pleorotus ostreatus inhibits proliferation of human breast cancer and colon cancer cells through p53-dependent as well as p53-independent pathway. Int J Oncol. 2008;33:1307-13.

43. Jiang J, Slívova V, Harvey K. Valachovicova T, Sliva D. Ganoderma lucidum suppresses growth of breast cancer cells though the inhibition o f Akt/NF-Kappa b signaling. Nutr Cancer. 2004;49:209-16, doi: 10. 1 207/s15327914nc4902–13.

44. Talorete T P, Isoda H, Maekawa T. Agaricus blazei (class Basidio mycotina) aqueous extract enhances the expression of c-Jun protein in MCF-7 cells. J Agric Food Chem. 2002;50:5162-6, doi: 10.1021/jf011566p.

45. V etvicka V, Vashisht A, Saraswat-Ohri S, Vetvickova J. Immunological effects of yeast and mushroom derived beta-glucans. J Med Food. 2008;11:615-22, doi: 10.1089/jmf.2007.0588.

46. Israilides C, Klets D, Arapoglou D, Philippousis A, Pratsinis H, Ebringeró va A, et al. In vitro cytostatic and immunomodulatory p roperties of the medicinal mushroom Lentinus edodes. Phytome d icine. 2008;15:512-9, doi: 10.1016/j.phymed.2007.11.029.

47. Sliva D, Jedinak A, Kawasaki J, Harvey K, Shirov V. Phellinus linteus suppresses growth, angiogenesis and invasive behaviour of breast cancer cells through the inhibition of AKT signalling. Br J Cancer. 2008;98:1348 56, doi: 10.1038/sj.bjc.6604319.

48. Gennari JL, Veronesi R, Gennari MS. Edible mushroom Agaricus sylvaticus used as therapeutics complement in a patient with breast cancer and lung metastasis. Rev Bras Med. 2002;59:537-8.

49. See D, Mason S, Roshan R. Increased tumor necrosis factor alpha (TNFalpha) and natural killer cell (NK) function using an integrative approach in late stage cancers. Immunol Invest. 2002;31:137-53, doi: 10. 1081/IMM-120004804.

Received for publication on May 26, 2011; First review completed on June 26, 2011; Accepted for publication on July 18, 2011

No potential conflict of interest was reported.

E-mail: [e-mail]

Tel.: [phone]

Publication Dates

• Publication in this collection
  20 Dec 2011
• Date of issue
  2011

History

• Accepted
  18 July 2011
• Reviewed
  26 June 2011
• Received
  26 May 2011